HILS - Hillstream BioPharma, Inc.
Chart Events
Momentum
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.3690 |
| Open | 0.3680 |
| Bid | 0.3450 x 1200 |
| Ask | 0.3508 x 1200 |
| Day's Range | 0.3450 - 0.3690 |
| 52 Week Range | 0.3030 - 2.6500 |
| Volume | |
| Avg. Volume | 656,033 |
| Market Cap | 5.9M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6700 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
Fair Value
Related Research
GlobeNewswireHillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson
Appointment to Enhance Board’s Expertise Across Investments, Business Development and Capital Markets Kelly Anderson Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson BRIDGEWATER, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism r
ACCESSWIRESidoti's Micro-Cap Virtual May Conference
Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day May Micro-cap Conference taking place Wednesday and Thursday, May 10-11, 2023. Presentation schedule is subject to change, please visit www.sidoti.com/events for the most updated version and webinar links.
GlobeNewswireHillstream BioPharma Announces Closing of Public Offering of Common Stock
BRIDGEWATER, N.J., May 02, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death, and immuno-oncology targeted novel biologics, today announced the closing of its previously announced public offering of common stock. Hillstream sold 5,300,000 shares of
- GlobeNewswire
Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences
12th Drug Discovery Strategic Summit, being held May 3-4 in Boston, MA Sidoti Micro-Cap Virtual Conference, being held virtually on May 10-11 World Orphan Drug Congress, being held May 23-25 in Washington, D.C. BRIDGEWATER, N.J., May 02, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers, using proprietary ferroptosis with immuno-oncology tar
- GlobeNewswire
Hillstream BioPharma Announces Pricing of Public Offering
BRIDGEWATER, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death, and immuno-oncology targeted novel biologics, today announced the pricing of an underwritten public offering of 5,300,000 shares of its common stock. Each share is bein
- GlobeNewswire
Hillstream BioPharma Announces Proposed Public Offering
BRIDGEWATER, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death, and immuno-oncology targeted novel biologics, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants (“Pre-Funded Warra
- GlobeNewswire
Hillstream BioPharma Selects OncoBay Clinical to Advance Clinical and Regulatory Development for its Lead Drug Candidate HSB-1216, an Anti-Cancer Mechanism
OncoBay Clinical is a boutique clinical research organization (CRO) that is a subsidiary of the Moffitt Cancer Center and has extensive experience in oncology drug developmentBRIDGEWATER, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell
ACCESSWIREHillstream BioPharma’s Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow
A surge in oncology drug development, coupled with increased patient access and early diagnosis, has resulted in a massive increase in global spending on cancer treatments.
- GlobeNewswire
Hillstream BioPharma Announces Pharmacokinetic Data of HSB-1216 Supportive of its Development Strategy and Pre-clinical Data
In IND-enabling studies, HSB-1216 remained tightly bound within the Quatramer™ until reaching its tumor target, consistent with earlier pre-clinical studies demonstrating reduction of tumor growthBRIDGEWATER, N.J., April 10, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing a portfolio of therapeutic candidates targeting drug resistant and devastating cancers, announced pharmacokinetic (PK) data of HSB-1216 supp
- GlobeNewswire
Hillstream BioPharma to Participate in Two Major Industry Conferences in April 2023
Company will present and hold 1x1s at the 2023 BioNJ BioPartnering Conference April 17-18 & CPHI North America Conference April 25-27BRIDGEWATER, N.J., March 28, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, and immuno-oncology targeted novel biologics, today announced that its CEO Randy Milby will be participating – i
- GlobeNewswire
Hillstream BioPharma to Attend the 35th Annual ROTH Conference on March 12-14, 2023
Management will hold 1-on-1 meetings with institutional investors and analystsCompany recently signed an exclusive option agreement with Applied Biomedical Science Institute (ABSI) to license technology for HER2 and HER3 BRIDGEWATER, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-canc
- GlobeNewswire
Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
Company Hosted its R&D Day to Discuss Product and Pipeline Goals Across 4 Pipeline Candidates and its Quatramer™ Tumor-Targeting Platform; Multiple inflection points over the next 12-18 Months Company’s Novel Emerging Anti-Cancer Mechanism, Ferroptosis, Addresses Potential Key Target Oncology Markets Projected to reach $11 Billion in 2028 Signs Exclusive Option Agreement with Applied Biomedical Science Institute to License Technology for HER2 and HER3 to be Developed for Potential Treatments Aga
- GlobeNewswire
Hillstream BioPharma Provides Webcast for its R&D Day on February 14th, 2023 at 10:00am ET
Company’s Novel Emerging Anti-Cancer Mechanism, Ferroptosis, Addresses Potential Key Target Oncology Markets Projected to reach $11 Billion in 2028 Signs Exclusive Option Agreement with Applied Biomedical Science Institute to License Technology for HER2 and HER3 to be Developed for Potential Treatments Against Drug Resistant Cancers Including HER2-Positive Metastatic Breast Cancer, Gastric Cancer, Lung Cancer and Ovarian Cancer Highlight Recent Preclinical Study of its Lead Drug Candidate HSB-12
- GlobeNewswire
Hillstream BioPharma Signs Exclusive Option Agreement with Applied Biomedical Science Institute (ABSI) to License Technology for HER2 and HER3 to be Developed for Potential Treatments Against Drug Resistant Cancers Including HER2-Positive Metastatic Breast Cancer, Gastric Cancer, Lung Cancer and Ovarian Cancer
HER2 and HER3 Conformational Domain Bridging Epitopes in Antibodies via an Exclusive Option Allows Hillstream BioPharma to Develop Proprietary Multi-format Biologics (bispecific, ADC, CAR-T) against Drug Resistant Breast and Gastric Cancers Anti-HER2 and Anti-HER3 monoclonal antibodies could be effective against a number of epithelial tumors including HER2-positive metastatic breast cancer, gastric cancer, lung cancer and ovarian cancer Antibody CDRs against HER2 and HER3 Conformational Domain B
GlobeNewswireIn a KRAS G12C-mutated NSCLC cell line, Calu-1, Hillstream BioPharma Demonstrated Significantly Greater Tumor Inhibition Combining Pembrolizumab, an anti-PD-1 antibody, and HSB-1216, a Ferroptosis Inducer
Hillstream BioPharma announces initial results of HSB-1216 synergy In a KRAS G12C-mutated NSCLC cell line, Calu-1, Hillstream BioPharma Demonstrated Significantly Greater Tumor Inhibition Combining Pembrolizumab, an anti-PD-1 antibody, and HSB-1216, a Ferroptosis Inducer Synergy and crosstalk between Ferroptosis and the Anti-PD-1 Pathways in KRAS G12C-mutated non-small cell lung cancer (NSCLC) cells Lung cancer remains one of the leading causes of cancer-related deaths worldwide NSCLC accounts f
- GlobeNewswire
Hillstream BioPharma Announces Acceptance of Abstract at AACR 2023 Annual Meeting Highlighting HSB-510 as Novel Bi-functional Inhibitor for Solid Tumors & Leukemias
Preclinical Update on HSB-510 and navitoclax, a Novel Quatramer™-based, First-in-Class Dual Inhibitor of PI3-Kδ/HDAC6 in combination with navitoclax (BCL-XL/BCL-2 inhibitor) BRIDGEWATER, N.J., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell de
- GlobeNewswire
Hillstream BioPharma to Host Virtual R&D Day to Showcase its Emerging Immuno-oncology Pipeline Targeting Drug-Resistant Cancers
Quatramer-based HSB-1216 combined with anti-MUC1-C antibody designed to target cancer stem cells (CSCs) by inducing ferroptosis in drug resistant cancers HSB-1940, an anti-PD-1 Quatrabody™, is a proprietary targeted IO biologic BRIDGEWATER, N.J., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new an
BenzingaWhy Are Hillstream BioPharma Shares Trading Over 100% Today?
Hillstream BioPharma Inc (NASDAQ: HILS) signed an exclusive option agreement with Dana-Farber Cancer Institute to license technology targeting the MUC1-C oncoprotein. The MUC1 gene was identified by Dr. Donald Kufe, Physician and Researcher at Dana-Farber, based on its overexpression in human cancers. Dr. Kufe has demonstrated that MUC1-C is necessary for multiple cancer cell hallmarks. Dana-Farber has granted under an exclusive option agreement to Hillstream Biopharma Inc certain of its proprie
- GlobeNewswire
Hillstream BioPharma Signs an Exclusive Option Agreement to Advance Next-Generation Anti-MUC1-C Agents for Drug Resistant Cancers
Development expected to capitalize upon tumor targeting Quatramers™ MUC1-C could be effective against a number of drug resistant cancers such as metastatic triple negative breast cancer (TNBC), small cell lung cancer (SCLC), merkel cell carcinoma (MCC) and neuroendocrine prostate cancer (NEPC) BRIDGEWATER, N.J., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream”, or the “Company”), a biotechnology company developing novel therapeutic candidates targeting fe
- GlobeNewswire
Hillstream BioPharma to Present at the Virtual Sidoti Micro-Cap Conference on January 18-19, 2023
BRIDGEWATER, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, will present at the Virtual Sidoti Micro-Cap Conference being held on January 18-19, 2023. Mr. Randy Milby, Founder and Chief Executive Officer of Hillstream BioPhar
- ACCESSWIRE
Sidoti's January Micro-Cap Conference
Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 18-19, 2023.
Simply Wall St.Insiders who purchased Hillstream BioPharma, Inc. (NASDAQ:HILS) stock last year recover some losses which currently stand at US$86k
Insiders who purchased US$104k worth of Hillstream BioPharma, Inc. ( NASDAQ:HILS ) shares over the past year recouped...
- GlobeNewswire
Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies™ (HSB-1940) against PD-1, by combining Quatramers™ with OmniAb’s Picobodies™, via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated Targets
Collaboration allows Hillstream to enter the rapidly growing Immuno-oncology therapeutics market By capitalizing on the long half-life of tumor targeting Quatramers™ combined with OmniTaur™-derived Picobodies™, the lead program, HSB-1940, is being developed to target PD-1 Picobodies are the smallest known antibody fragment, comprised of ultra-long CDR H3 sequences of 30-40 amino acids rich with cysteines that create tightly folded structures capable of binding recessed epitopes BRIDGEWATER, N.J.
- GlobeNewswire
Hillstream BioPharma to Present at the RHK Capital Disruptive Growth Conference on December 5-6, 2022
BRIDGEWATER, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, will present at the 2022 RHK Capital Disruptive Growth Conference hosted at Reed Smith in New York City on December 5-6, 2022. Mr. Randy Milby, Founder and Chief Exe
- GlobeNewswire
Hillstream’s New Anti-Cancer Mechanism Quatramer-based Ferroptosis Inducer, HSB-1216 Abstract Available for Viewing at EORTC-NCI-AACR Symposium
Abstract highlights data from HSB-1216 in acute myeloid leukemia (AML) growthBRIDGEWATER, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (“Hillstream”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, today announced that an abstract highlighting the progress of the Quatramer-based Ferroptosis Inducer, HSB-1216, are ava